A Phase III, Multicentre, Randomised, Open-label, Parallel, Active-controlled Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Jul 2019
Price : $35 *
At a glance
- Drugs Triptorelin (Primary)
- Indications Endometriosis
- Focus Therapeutic Use
- Sponsors Ipsen
- 27 Mar 2019 Planned End Date changed from 28 Feb 2020 to 1 Dec 2019.
- 27 Mar 2019 Planned primary completion date changed from 31 Oct 2019 to 17 May 2019.
- 27 Mar 2019 Status changed from recruiting to active, no longer recruiting.